DARA BioSciences is collaborating with America Stem Cell (ASC) to expand on observations from recent preclinical studies. The results showed that dipeptidylpeptidase (DPPIV) inhibitors has improved the efficiency of hematopoietic stem cell (HSC) transplants.
HSC transplants are used as a therapeutic approach for many malignant and non-malignant hematological disorders.
Reportedly, ASC will expand on these previous observations with preclinical studies, utilizing potent and selective DPPIV inhibitors obtained from DARA.
The goal of this collaboration is to accelerate the translation of this approach to the clinic, for the benefit of many patients in need of a HSC transplant.
DARA BioSciences is a development-stage pharmaceutical company that acquires promising therapeutic small molecules, and develops them for subsequent sale or out-licensing to larger pharmaceutical companies.
America Stem Cell is dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cells.